Library
BCM-95® (CURCUGREEN®), 20 Mar 2013
Published on : 2013
Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis
Reji Kizhakkedath
PMID: 24002213 DOI: 10.3892/mmr.2013.1661
A formulation containing Curcuma longa and Boswellia serrata extracts (CB formulation) was evaluated for safety and efficacy in osteoarthritic patients and directly compared with the selective COX-2 inhibitor, celecoxib. In total, 54 subjects were screened, 30 subjects were enrolled and 28 completed the study. The treatment was well tolerated and did not produce any adverse effect in patients, as judged by the vital signs, hemogram, liver and renal function tests. The CB formulation at 500 mg administered twice a day, was more successful than administering celecoxib 100 mg twice a day for symptom scoring and clinical examination. The formulation was found to be safe and no dose-related toxicity was found.
https://pubmed.ncbi.nlm.nih.gov/24002213/
https://www.spandidos-publications.com/10.3892/mmr.2013.1661
Keywords
- BCM-95
- bcm95
- boswellia serratta
- curcugreen
- osteoarthritis
Request More Information
Increase your business growth potential with our patented extracts
Let’s collaborate to refine your ideas or built from scratch
Arjuna Natural
Arjuna Natural is India’s leading manufacturer and exporter of standardized botanical extracts for pharmaceutical and nutraceutical industries for more than two decades. Established in 1989, the company has grown...Read More
